DALLAS, TX — February 13, 2002 — Bextra® (valdecoxib), a new COX-2 specific inhibitor, demonstrated effective post-operative pain relief and significantly reduced patient consumption of the opioid analgesic morphine, when administered post-operatively to patients undergoing knee replacement surgery, according to an investigational study presented this week at the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS).
Valdecoxib was recently approved by the U.S. Food and Drug Administration for the treatment of osteoarthritis, adult rheumatoid arthritis, and primary dysmenorrhea (menstrual cramps).
SOURCE: Pharmacia Corporation
לכתבה המלאה הקליקו על הקישור
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!